Fresenius Medical Care (ETR:FME) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?

Key Points

• FME slipped below its 200-day moving average — the 200‑day MA is €41.64, the stock traded as low as €39.20 and last at €39.48 on volume of 930,989 shares.
• Valuation and leverage — market cap $11.76 billion, P/E 17.84 and PEG 0.42, with a high debt-to-equity ratio of 102.95 indicating significant leverage.
• Business profile — Fresenius Medical Care runs a global network of outpatient dialysis clinics and provides dialysis treatment, supplies, diagnostics and hospital-contracted renal care.

Fresenius Medical Care AG (ETR:FME - )'s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of €41.64 and traded as low as €39.20. Fresenius Medical Care shares last traded at €39.48, with a volume of 930,989 shares changing hands.

Fresenius Medical Care Price Performance

The stock's 50-day moving average is €39.27 and its 200 day moving average is €41.64. The stock has a market capitalization of $11.76 billion, a PE ratio of 17.84, a P/E/G ratio of 0.42 and a beta of 0.86. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 102.95.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.